ArticlePloS one2013
Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2019Pooled it
- Global DNA hypomethylation in prostate cancer development and progression: a systematic review.Prostate cancer and prostatic diseases · 2015Pooled it
- Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer.Cancer metastasis reviews · 2026Review
- Methylation status of GSTP1 and APC promoter genes as potential biomarkers for early detection and tumor aggressiveness in prostate cancer: insights from a Moroccan cohort.Molecular biology reports · 2025Article
- Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort.Frontiers in oncology · 2023Article
- Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients.Frontiers in oncology · 2023Review
- Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.Virchows Archiv : an international journal of pathology · 2020Article
- The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies.Antioxidants (Basel, Switzerland) · 2020Review
- Review
- Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer.Clinical epigenetics · 2020Article
- Review
- DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer.Clinical epigenetics · 2019Article
- Differential gene methylation patterns in cancerous and non‑cancerous cells.Oncology reports · 2019Article
- Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality.Prostate cancer and prostatic diseases · 2019Article
- Integrated Bioinformatics Analysis of Potential Biomarkers for Prostate Cancer.Pathology oncology research : POR · 2019Article
- DNA methylation profiles in African American prostate cancer patients in relation to disease progression.Genomics · 2019Article
- Increased paracellular permeability of tumor-adjacent areas in 1,2-dimethylhydrazine-induced colon carcinogenesis in rats.Cancer biology & medicine · 2018Article
- Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.Scientific reports · 2017Article
- LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.Epigenetics · 2017Article
- Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.The Prostate · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMarkers that can discriminate between indolent and aggressive prostate tumours are needed. We studied gene methylation in non-neoplastic tissue adjacent to prostate tumour (NTAT) in association with prostate cancer mortality.
methodsFrom two cohorts of consecutive prostate cancer patients diagnosed at one pathology ward in Turin, Italy, we selected 157 patients with available NTAT and followed them up for more than 14 years. We obtained DNA from NTAT in paraffin-embedded prostate tumour tissues and used probe real-time PCR to analyse methylation of the glutathione S-transferase (GSTP1) and adenomatous polyposis coli (APC) gene promoters.
resultsPrevalence of APC and GSTP1 methylation in the NTAT was between 40 and 45%. It was associated with methylation in prostate tumour tissue for the same two genes as well as with a high Gleason score. The hazard ratio (HR) of prostate cancer mortality was 2.38 (95% confidence interval: 1.23-4.61) for APC methylation, and 2.92 (1.49-5.74) for GSTP1 methylation in NTAT. It changed to 1.91 (1.03-3.56) and 1.60 (0.80-3.19) after adjusting for Gleason score and methylation in prostate tumour tissue. Comparison of 2 vs. 0 methylated genes in NTAT revealed a HR of 4.30 (2.00-9.22), which decreased to 2.40 (1.15-5.01) after adjustment. Results were stronger in the first 5 years of follow-up (adjusted HR: 3.29, 95% CI: 1.27-8.52).
conclusionsChanges in gene methylation are an early event in prostate carcinogenesis and may play a role in cancer progression. Gene methylation in NTAT is a possible prognostic marker to be evaluated in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.